Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups.

Dodd LE, Follmann D, Proschan M, Wang J, Malvy D, van Griensven J, Ciglenecki I, Horby PW, Ansumana R, Jiang JF, Davey RT, Lane HC, Gouel-Cheron A.

Sci Transl Med. 2019 Nov 27;11(520). pii: eaaw1049. doi: 10.1126/scitranslmed.aaw1049.

PMID:
31776287
2.

Post-treatment Lyme disease symptoms score: Developing a new tool for research.

Turk SP, Lumbard K, Liepshutz K, Williams C, Hu L, Dardick K, Wormser GP, Norville J, Scavarda C, McKenna D, Follmann D, Marques A.

PLoS One. 2019 Nov 11;14(11):e0225012. doi: 10.1371/journal.pone.0225012. eCollection 2019.

3.

Analysis Populations in Anti-Infective Clinical Trials: Whom to Analyze?

Evans S, Rubin DB, Powers JH, Follmann D.

Stat Commun Infect Dis. 2018 Dec;10(1). pii: 20170002. doi: 10.1515/scid-2017-0002. Epub 2018 Aug 29.

4.

Attributable mortality from extensively drug-resistant gram-negative infections using propensity-matched tracer antibiotic algorithms.

Kadri SS, Strich JR, Swihart BJ, Hohmann S, Dekker JP, Palmore T, Bonne S, Freeman B, Raybould J, Shah NG, Patel D, Husson J, Jacobs MD, Duong L, Follmann D, Hooper DC, Timpone J, Danner RL.

Am J Infect Control. 2019 Sep;47(9):1040-1047. doi: 10.1016/j.ajic.2019.01.010. Epub 2019 Feb 27.

PMID:
30824387
5.

Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS).

Evans SR, Follmann D, Liu Y, Holland T, Doernberg SB, Rouphael N, Hamasaki T, Jiang Y, Lok JJ, Tran TTT, Harris AD, Fowler VG, Boucher H, Kreiswirth BN, Bonomo RA, Van Duin D, Paterson DL, Chambers H.

Clin Infect Dis. 2019 May 17;68(11):1961-1967. doi: 10.1093/cid/ciy912.

6.

Predictive cluster level surrogacy in the presence of interference.

Gabriel EE, Follmann DA.

Biostatistics. 2018 Sep 21. doi: 10.1093/biostatistics/kxy050. [Epub ahead of print]

PMID:
30247535
7.

Half blind superiority tests for clinical trials of anti-infective drugs.

Follmann D, Brittain E, Lumbard K.

Stat Med. 2019 Jan 15;38(1):31-43. doi: 10.1002/sim.7954. Epub 2018 Sep 10.

PMID:
30203497
8.

Reliably picking the best endpoint.

Follmann D.

Stat Med. 2018 Dec 20;37(29):4374-4385. doi: 10.1002/sim.7927. Epub 2018 Aug 8.

PMID:
30091264
9.

Response to letter by Antonio Martín Andrés on "A boundary-optimized rejection region test for the two-sample binomial problem".

Gabriel EE, Nason M, Fay MP, Follmann D.

Stat Med. 2018 Jun 30;37(14):2303-2306. doi: 10.1002/sim.7684. No abstract available.

PMID:
29864228
10.

Causal estimands and confidence intervals associated with Wilcoxon-Mann-Whitney tests in randomized experiments.

Fay MP, Brittain EH, Shih JH, Follmann DA, Gabriel EE.

Stat Med. 2018 Sep 10;37(20):2923-2937. doi: 10.1002/sim.7799. Epub 2018 May 17.

11.

A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection.

Gautam R, Nishimura Y, Gaughan N, Gazumyan A, Schoofs T, Buckler-White A, Seaman MS, Swihart BJ, Follmann DA, Nussenzweig MC, Martin MA.

Nat Med. 2018 May;24(5):610-616. doi: 10.1038/s41591-018-0001-2. Epub 2018 Apr 16.

12.

Streptococcal group A, C and G pharyngitis in school children: a prospective cohort study in Southern India.

Jose JJM, Brahmadathan KN, Abraham VJ, Huang CY, Morens D, Hoe NP, Follmann DA, Krause RM.

Epidemiol Infect. 2018 May;146(7):848-853. doi: 10.1017/S095026881800064X. Epub 2018 Apr 4.

13.

Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay.

Logue J, Tuznik K, Follmann D, Grandits G, Marchand J, Reilly C, Sarro YDS, Pettitt J, Stavale EJ, Fallah M, Olinger GG, Bolay FK, Hensley LE.

J Virol Methods. 2018 May;255:84-90. doi: 10.1016/j.jviromet.2018.02.018. Epub 2018 Feb 23.

14.

Conditional independence test by generalized Kendall's tau with generalized odds ratio.

Ji S, Ning J, Qin J, Follmann D.

Stat Methods Med Res. 2018 Nov;27(11):3224-3235. doi: 10.1177/0962280217695345. Epub 2017 Feb 23.

15.

A boundary-optimized rejection region test for the two-sample binomial problem.

Gabriel EE, Nason M, Fay MP, Follmann DA.

Stat Med. 2018 Mar 30;37(7):1047-1058. doi: 10.1002/sim.7579. Epub 2017 Dec 26.

PMID:
29280170
16.

Sieve analysis using the number of infecting pathogens.

Follmann D, Huang CY.

Biometrics. 2018 Sep;74(3):1023-1033. doi: 10.1111/biom.12833. Epub 2017 Dec 14.

17.

Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia.

Kennedy SB, Bolay F, Kieh M, Grandits G, Badio M, Ballou R, Eckes R, Feinberg M, Follmann D, Grund B, Gupta S, Hensley L, Higgs E, Janosko K, Johnson M, Kateh F, Logue J, Marchand J, Monath T, Nason M, Nyenswah T, Roman F, Stavale E, Wolfson J, Neaton JD, Lane HC; PREVAIL I Study Group.

N Engl J Med. 2017 Oct 12;377(15):1438-1447. doi: 10.1056/NEJMoa1614067.

18.

Genetic progress in sunflower crop in Rio Grande do Sul State, Brazil.

Follmann DN, Cargnelutti Filho A, Lorentz LH, Boligon AA, Caraffa M, Wartha CA.

Genet Mol Res. 2017 Apr 13;16(2). doi: 10.4238/gmr16029520.

PMID:
28407182
19.

Genetic progress in homogeneous regions of wheat cultivation in Rio Grande do Sul State, Brazil.

Follmann DN, Cargnelutti Filho A, Lúcio AD, de Souza VQ, Caraffa M, Wartha CA.

Genet Mol Res. 2017 Mar 30;16(1). doi: 10.4238/gmr16019517.

PMID:
28363003
20.

REML/BLUP and sequential path analysis in estimating genotypic values and interrelationships among simple maize grain yield-related traits.

Olivoto T, Nardino M, Carvalho IR, Follmann DN, Ferrari M, Szareski VJ, de Pelegrin AJ, de Souza VQ.

Genet Mol Res. 2017 Mar 22;16(1). doi: 10.4238/gmr16019525.

PMID:
28340272
21.

Semiparametric pseudoscore for regression with multidimensional but incompletely observed regressor.

Hu Z, Qin J, Follmann D.

Stat Med. 2018 Jan 30;37(2):207-217. doi: 10.1002/sim.7253. Epub 2017 Feb 16.

PMID:
28211087
22.

Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis With Vasopressor-Dependent Shock: A Propensity Score-Matched Analysis From 130 US Hospitals.

Kadri SS, Swihart BJ, Bonne SL, Hohmann SF, Hennessy LV, Louras P, Evans HL, Rhee C, Suffredini AF, Hooper DC, Follmann DA, Bulger EM, Danner RL.

Clin Infect Dis. 2017 Apr 1;64(7):877-885. doi: 10.1093/cid/ciw871.

23.

Genetic progress in oat associated with fungicide use in Rio Grande do Sul, Brazil.

Follmann DN, Cargnelutti Filho A, Lúcio AD, de Souza VQ, Caraffa M, Wartha CA.

Genet Mol Res. 2016 Dec 19;15(4). doi: 10.4238/gmr15049390.

PMID:
28002614
24.

Sample sizes to estimate mean values for tassel traits in maize genotypes.

Wartha CA, Cargnelutti Filho A, Lúcio AD, Follmann DN, Kleinpaul JA, Simões FM.

Genet Mol Res. 2016 Nov 21;15(4). doi: 10.4238/gmr15049151.

PMID:
27886348
25.

Early Fungicidal Activity as a Candidate Surrogate Endpoint for All-Cause Mortality in Cryptococcal Meningitis: A Systematic Review of the Evidence.

Montezuma-Rusca JM, Powers JH, Follmann D, Wang J, Sullivan B, Williamson PR.

PLoS One. 2016 Aug 4;11(8):e0159727. doi: 10.1371/journal.pone.0159727. eCollection 2016. Review.

26.

Non-inferiority tests for anti-infective drugs using control group quantiles.

Fay MP, Follmann DA.

Clin Trials. 2016 Dec;13(6):632-640. Epub 2016 Jul 17.

27.

Who really gets strep sore throat? Confounding and effect modification of a time-varying exposure on recurrent events.

Follmann D, Huang CY, Gabriel E.

Stat Med. 2016 Oct 30;35(24):4398-4412. doi: 10.1002/sim.7000. Epub 2016 Jun 16.

28.

Recurrent event data analysis with intermittently observed time-varying covariates.

Li S, Sun Y, Huang CY, Follmann DA, Krause R.

Stat Med. 2016 Aug 15;35(18):3049-65. doi: 10.1002/sim.6901. Epub 2016 Feb 16.

29.

Augmented trial designs for evaluation of principal surrogates.

Gabriel EE, Follmann D.

Biostatistics. 2016 Jul;17(3):453-67. doi: 10.1093/biostatistics/kxv055. Epub 2016 Jan 28.

30.

Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges.

Kennedy SB, Neaton JD, Lane HC, Kieh MW, Massaquoi MB, Touchette NA, Nason MC, Follmann DA, Boley FK, Johnson MP, Larson G, Kateh FN, Nyenswah TG.

Clin Trials. 2016 Feb;13(1):49-56. doi: 10.1177/1740774515621037. Epub 2016 Jan 14.

PMID:
26768572
31.

Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation.

Evans SR, Follmann D.

Stat Biopharm Res. 2016;8(4):386-393. doi: 10.1080/19466315.2016.1207561. Epub 2016 Dec 6.

32.

Reply to Phillips, Morris, and Walker.

Evans S, Follmann D, Schoenfeld D, Fowler VG Jr, Chambers HF.

Clin Infect Dis. 2016 Mar 15;62(6):815-6. doi: 10.1093/cid/civ1003. Epub 2015 Dec 9. No abstract available.

33.

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.

Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ, Corey L, Mascola JR, Graham BS, Sobieszczyk ME, Kublin JG, Robertson M, Hammer SM, Gray GE, Buchbinder SP, Gilbert PB.

PLoS One. 2015 Sep 2;10(9):e0136626. doi: 10.1371/journal.pone.0136626. eCollection 2015.

34.

CD8(+) T-cell Cytotoxic Capacity Associated with Human Immunodeficiency Virus-1 Control Can Be Mediated through Various Epitopes and Human Leukocyte Antigen Types.

Migueles SA, Mendoza D, Zimmerman MG, Martins KM, Toulmin SA, Kelly EP, Peterson BA, Johnson SA, Galson E, Poropatich KO, Patamawenu A, Imamichi H, Ober A, Rehm CA, Jones S, Hallahan CW, Follmann DA, Connors M.

EBioMedicine. 2014 Dec 22;2(1):46-58. doi: 10.1016/j.ebiom.2014.12.009. eCollection 2015 Jan.

35.

Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR).

Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, Schoenfeld D, Chuang-Stein C, Cosgrove SE, Fowler VG Jr, Lautenbach E, Chambers HF.

Clin Infect Dis. 2015 Sep 1;61(5):800-6. doi: 10.1093/cid/civ495. Epub 2015 Jun 25.

36.

Estimation of mean response via effective balancing score.

Hu Z, Follmann DA, Wang N.

Biometrika. 2014 Sep;101(3):613-624.

37.

Incorporating founder virus information in vaccine field trials.

Follmann D, Huang CY.

Biometrics. 2015 Jun;71(2):386-96. doi: 10.1111/biom.12277. Epub 2015 Mar 13.

38.

Vaccine design via nonnegative lasso-based variable selection.

Hu Z, Follmann DA, Miura K.

Stat Med. 2015 May 10;34(10):1791-8. doi: 10.1002/sim.6452. Epub 2015 Feb 2.

39.

Comment: Fundamentals and Innovation in Antibiotic Trials.

Evans SR, Follmann D.

Stat Biopharm Res. 2015;7(4):331-336. Epub 2015 Dec 17. No abstract available.

40.

Mycobacterial antigen driven activation of CD14++CD16- monocytes is a predictor of tuberculosis-associated immune reconstitution inflammatory syndrome.

Andrade BB, Singh A, Narendran G, Schechter ME, Nayak K, Subramanian S, Anbalagan S, Jensen SM, Porter BO, Antonelli LR, Wilkinson KA, Wilkinson RJ, Meintjes G, van der Plas H, Follmann D, Barber DL, Swaminathan S, Sher A, Sereti I.

PLoS Pathog. 2014 Oct 2;10(10):e1004433. doi: 10.1371/journal.ppat.1004433. eCollection 2014 Oct.

41.

On the design and analysis of clinical trials with correlated outcomes.

Follmann D, Proschan M.

Contemp Clin Trials. 2014 Sep;39(1):86-94. doi: 10.1016/j.cct.2014.08.001. Epub 2014 Aug 8.

42.

Matched longitudinal analysis of biomarkers associated with survival.

Dodd LE, Johnson RF, Blaney JE, Follmann D.

Clin Vaccine Immunol. 2014 Aug;21(8):1145-52. doi: 10.1128/CVI.00252-14. Epub 2014 Jun 18.

43.

A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response.

Talaat KR, Luke CJ, Khurana S, Manischewitz J, King LR, McMahon BA, Karron RA, Lewis KD, Qin J, Follmann DA, Golding H, Neuzil KM, Subbarao K.

J Infect Dis. 2014 Jun 15;209(12):1860-9. doi: 10.1093/infdis/jiu123. Epub 2014 Mar 5. Erratum in: J Infect Dis. 2014 Dec 15;210(12):2021.

44.

Discordant minimum inhibitory concentration analysis: a new path to licensure for anti-infective drugs.

Follmann D, Brittain E, Powers JH.

Clin Trials. 2013;10(6):876-85. doi: 10.1177/1740774513507503.

45.

Enhanced effector function of CD8(+) T cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-activated receptor 1.

Hurley A, Smith M, Karpova T, Hasley RB, Belkina N, Shaw S, Balenga N, Druey KM, Nickel E, Packard B, Imamichi H, Hu Z, Follmann D, McNally J, Higgins J, Sneller M, Lane HC, Catalfamo M.

J Infect Dis. 2013 Feb 15;207(4):638-50. doi: 10.1093/infdis/jis730. Epub 2012 Nov 29.

46.

Linezolid for treatment of chronic extensively drug-resistant tuberculosis.

Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon HS, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park SK, Cho SN, Barry CE 3rd.

N Engl J Med. 2012 Oct 18;367(16):1508-18. doi: 10.1056/NEJMoa1201964.

47.

Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge.

Fay MP, Follmann DA, Lynn F, Schiffer JM, Stark GV, Kohberger R, Quinn CP, Nuzum EO.

Sci Transl Med. 2012 Sep 12;4(151):151ra126. doi: 10.1126/scitranslmed.3004073.

48.

Bounds on the effect of vaccine induced immune response on outcome.

Follmann D, Fay M.

Int J Biostat. 2012 Jan 6;8(2). pii: /j/ijb.2012.8.issue-2/1557-4679.1348/1557-4679.1348.xml. doi: 10.2202/1557-4679.1348.

PMID:
22499733
49.

A valid formulation of the analysis of noninferiority trials under random effects meta-analysis.

Brittain EH, Fay MP, Follmann DA.

Biostatistics. 2012 Sep;13(4):637-49. doi: 10.1093/biostatistics/kxs006. Epub 2012 Mar 30.

50.

Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease.

Ledwaba L, Tavel JA, Khabo P, Maja P, Qin J, Sangweni P, Liu X, Follmann D, Metcalf JA, Orsega S, Baseler B, Neaton JD, Lane HC; Project Phidisa Biomarkers Team.

PLoS One. 2012;7(3):e24243. doi: 10.1371/journal.pone.0024243. Epub 2012 Mar 20.

Supplemental Content

Loading ...
Support Center